10-QPeriod: Q2 FY2009

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2009

Filed August 7, 2009For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed its 10-Q for the quarterly period ending June 30, 2009. As a clinical-stage biopharmaceutical company, ALNY's financial performance and operational progress are heavily scrutinized by investors for signs of future revenue potential and the advancement of its pipeline. The company is focused on developing RNA interference (RNAi) therapeutics. During this period, ALNY continued its operations with a significant net loss, typical for a company in its development stage, highlighting the substantial investment required for drug research and development. Investors are keenly watching the progress of its key drug candidates and strategic partnerships which are crucial for its long-term success and potential to reach commercialization.

Financial Highlights

23 data points
Beta

Revenue

$24.60M

Net Income

-$22.70M

-92.3% Net Margin

Cash & Equivalents

$147.87M

Free Cash Flow

-$37.63M

Financial Statements
Beta
Revenue$24.60M
R&D Expenses$38.62M
Operating Expenses$47.01M
Operating Income-$22.41M
Net Income-$22.70M

Key Highlights

  • 1ALNY reported a net loss for the three and six months ended June 30, 2009, consistent with its status as a clinical-stage biopharmaceutical company investing heavily in R&D.
  • 2The company's financial statements indicate significant operating expenses, primarily driven by research and development activities, reflecting the ongoing costs of advancing its RNAi therapeutic pipeline.
  • 3As of July 31, 2009, ALNY had approximately 41.7 million shares of Common Stock outstanding, providing a base for valuation metrics.
  • 4The filing includes an Amended and Restated Strategic Collaboration and License Agreement effective April 28, 2009, with Isis Pharmaceuticals, Inc., which could be a key driver for future revenue and pipeline advancement.
  • 5ALNY is identified as a large accelerated filer, indicating a certain scale and maturity in its reporting and operational processes.
  • 6The company is not a shell company, suggesting ongoing operational activities beyond mere shell corporation status.
  • 7Risk factors section (Item 1A) is likely to detail significant risks inherent in drug development, regulatory approval processes, and competitive market dynamics.

Frequently Asked Questions

Alnylam Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. As of this filing, the company is investing heavily in research and development, and its products are not yet commercialized, leading to net losses typical of this industry stage.

Investors should pay close attention to the net loss, operating expenses (especially R&D), cash burn rate, and cash reserves. The balance sheet will provide insights into the company's financial position, while the statements of operations will detail revenue (if any, likely from collaborations) and expenses. The statements of cash flows are crucial for understanding how the company is funding its operations.

Yes, the filing references an Amended and Restated Strategic Collaboration and License Agreement with Isis Pharmaceuticals, Inc., effective April 28, 2009. Such agreements are critical for clinical-stage biotechs as they can provide funding, validation, and a pathway to potential future revenue streams.

While not detailed in the provided excerpt, Item 1A, 'Risk Factors,' of a 10-Q filing typically outlines significant risks. For a company like Alnylam at this stage, these would likely include the inherent uncertainties and long timelines of drug development, the need for successful clinical trial outcomes, regulatory approval risks, intellectual property challenges, competition from other pharmaceutical companies, and the need for ongoing capital to fund operations.